201 related articles for article (PubMed ID: 17464308)
41. In focus: ECOG 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).
Clin Adv Hematol Oncol; 2004 Mar; 2(3):152. PubMed ID: 16166942
[No Abstract] [Full Text] [Related]
42. The difficulty of determining the route of intraocular penetration of gentamicin after subconjunctival injection in the rabbit.
Barza M; Kane A; Baum J
Invest Ophthalmol Vis Sci; 1981 Apr; 20(4):509-14. PubMed ID: 7216668
[TBL] [Abstract][Full Text] [Related]
43. Treatment of chronic ocular hypotony with intraocular application of sodium hyaluronate.
Küçükerdönmez C; Beutel J; Bartz-Schmidt KU; Gelisken F
Br J Ophthalmol; 2009 Feb; 93(2):235-9. PubMed ID: 18829633
[TBL] [Abstract][Full Text] [Related]
44. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
45. Intravitreal alemtuzumab penetrates full-thickness retina in rabbit eyes.
Ekdawi NS; Pulido JS; Itty S; Marler RJ; Herman DC; Hardwig P; Mohney BG; Valyi-Nagy T; Shukla D
Retina; 2009; 29(10):1532-4. PubMed ID: 19898186
[TBL] [Abstract][Full Text] [Related]
46. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
47. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
48. [Posterior vitreous detachment induced by intravitreal injection of the combination of chondroitinase ABC and matrix metalloproteinase-3].
Meng ZJ; Zeng SQ
Zhonghua Yan Ke Za Zhi; 2004 Sep; 40(9):625-31. PubMed ID: 15500769
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma.
Velez G; Yuan P; Sung C; Tansey G; Reed GF; Chan CC; Nussenblatt RB; Robinson MR
Arch Ophthalmol; 2001 Oct; 119(10):1518-24. PubMed ID: 11594954
[TBL] [Abstract][Full Text] [Related]
51. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
52. [Intraocular malignant lymphoma].
Brovkina AF; Sorokina MN; Kaplina AV
Vestn Oftalmol; 1990; 106(6):48-53. PubMed ID: 2075660
[TBL] [Abstract][Full Text] [Related]
53. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes.
Dejneka NS; Wan S; Bond OS; Kornbrust DJ; Reich SJ
Mol Vis; 2008 May; 14():997-1005. PubMed ID: 18523657
[TBL] [Abstract][Full Text] [Related]
54. Ocular toxicity after intravitreal injection of terconazole.
Schulman JA; Peyman GA; Dietlein J; Fiscella R; Colantino B
Ann Ophthalmol; 1989 Sep; 21(9):345-7. PubMed ID: 2817662
[TBL] [Abstract][Full Text] [Related]
55. [Intraocular availability of liposome encapsulated monoclonal antibodies in the rabbit model. Results of a pilot study].
Pleyer U; Rückert D; Bachmann W; Schmidt KH; Thiel HJ
Fortschr Ophthalmol; 1991; 88(6):870-4. PubMed ID: 1794824
[TBL] [Abstract][Full Text] [Related]
56. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe N; Tanimoto TE; Shimoda K; Hikiji W; Mitsugi K; Takase K; Henzan H; Numata A; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Haematologica; 2004 Jun; 89(6 Suppl):EIM14. PubMed ID: 15194556
[No Abstract] [Full Text] [Related]
57. Effects of a new hemostatic agent Ankaferd Blood Stopper(®)on the intraocular tissues in rat model.
Alpay A; Bektas S; Alpay A; Ugurbas SC; Evren C; Ugurbas SH
Cutan Ocul Toxicol; 2012 Jun; 31(2):128-31. PubMed ID: 22034855
[TBL] [Abstract][Full Text] [Related]
58. A case of primary intraocular lymphoma treated by intravitreal methotrexate.
Kim E; Kim C; Lee J; Cho Y
Korean J Ophthalmol; 2009 Sep; 23(3):210-4. PubMed ID: 19794951
[TBL] [Abstract][Full Text] [Related]
59. Investigation of kinetics of methotrexate for therapeutic treatment of intraocular lymphoma.
Palakurthi NK; Krishnamoorthy M; Augsburger JJ; Correa ZM; Banerjee RK
Curr Eye Res; 2010 Dec; 35(12):1105-15. PubMed ID: 20961217
[TBL] [Abstract][Full Text] [Related]
60. Botulinum toxin injection into rabbit vitreous.
Wienkers K; Helveston EM; Ellis FD; Cadera W
Ophthalmic Surg; 1984 Apr; 15(4):310-4. PubMed ID: 6728404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
